期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

二肽肽酶-4抑制剂西格列汀相关的药物相互作用 被引量：6

原文传递
导出
摘要 二肽肽酶-4(dipeptidyl peptidase-4,DPP-4)抑制剂通过抑制DPP-4酶活性,延长内源性GLP-1的生理半衰期,促进餐后胰岛素的分泌而降低2型糖尿病患者的餐后血糖。通过检索Medline文献,考察DPP-4抑制剂西格列汀与常见的抗高血压药物、口服抗糖尿病药物、调血脂药物、口服避孕药等临床常见药物合用的安全性和有效性,显示西格列汀与上述药物合用不存在临床意义的药动学方面的不良相互作用。
作者 金阳 刘治军
机构地区 卫生部北京医院药学部
出处 《中国医院药学杂志》 CAS CSCD 北大核心 2013年第13期1085-1088,共4页 Chinese Journal of Hospital Pharmacy
关键词 DPP-4抑制剂 西格列汀 药物相互作用 CYP3A4
分类号 R977 [医药卫生—药品]
  • 相关文献

参考文献17

  • 1Golightly LK,Drayna CC, McDermott MT. Comparative Clini-cal Pharmacokinetics of Dipeptidyl Peptidase-4 Inhibitors [J].Clin Pharmacokinet 2012,51 .8) :501-514.
  • 2Chu XY,Bleasby K,Yabut J.et al. Transport of the dipeptidylpeptidase-4 inhibitor sitagliptin by human organic anion trans-porter 3,organic anion transporting polypeptide 4C1 ,and multi-drug resistance P-glycoprotein [ J ]. J Pharmacol Exp Ther.2007,321(2):673-683.
  • 3Mistry GC.Bergman AJ.Zheng W.etal. Sitagliptin,an dipepti-dyl peptidase-4 inhibitor,does not alter the pharmacokinetics ofthe sulphonylurea.glyburide,in healthy subjects[J]. Br J ClinPharmacol,2008*66(1) :36-42.
  • 4Mistry GC,Bergman AJ,Luo Wet aL Multiple-dose adminis-tration of sitagliptin,a dipeptidyl peptidase-4 inhibitor,does notalter the single-dose pharmacokinetics of rosiglitazone inhealthy subjects[J]. J Clin Pharmacol, 2007,47(2) : 159-164.
  • 5Herman GA,Bergman A, Yi B,et al. Tolerability and pharma-cokinetics of metformin and the dipeptidyl peptidase-4 inhibitorsitagliptin when co-administered in patients with type 2 diabe-tes[J]. Curr Med Res Opin,2006,22(10) : 1939-1947.
  • 6Kasichayanula S,Liu X, Shyu WC, et al. Lack of pharmacoki-netic interaction between dapagliflozin, a novel sodium-glucosetransporter 2 inhibitor,and metformin.pioglitazone, glimepirideor sitagliptin in healthy subjects [J]. Diabetes Obes Metab,2011,13(1):47-54.
  • 7Smulders RA, Zhang W, Veltkamp SA, et al. No pharmacoki-netic interaction between ipragliflozin and sitagliptin, pioglita-zone, or glimepiride in healthy subject's [J ]. Diabetes ObesMetab ,2012,14(10); 937-943.
  • 8DiGregorio RV,Pasikhova Y. Rhabdomyolysis caused by a po-tential sitagliptin-lovastatin interaction [J]. Pharmacotherapy,2009,29(3):352-356.
  • 9Khao DP,Kohrt HE,Kugler J. Renal failure and rhabdomyoly-sis associated with sitagliptin and simvastatin use [J ]. DiabetMed,2(K)8,25 :1229 1230.
  • 10Boucher BJ. Renal failure and rhabdomyolysis associated withsitagliptin and simvastatin use. But what about the amiodarone[J]. Diabet Med,2009,26(2) ; 192-193.

同被引文献37

  • 1张婷.从2型糖尿病的发病机制中分析糖尿病治疗的新策略[J].世界临床医学,2017,11(10):128-129. 被引量：1
  • 2Muscelli E, Casolaro A, Gasldelli A, et al.Mechamisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes [J ]. J Clin Endocrinal Metab, 2012, 97 (8) : 2818 -2826.
  • 3Aso Y, Ozeki N, Terasawa T, et al. Serum level of soluble CD26/dipeptidyl peptidase - 4 (DPP- 4 ) predicts the response to sitsglip- tin, a DPP -4 inhibitor, in patients with type 2 diabetes controlled inadequately by metform- in and/or sulfonylurea [ J ]. Transl Res, 2012, 159 (1): 25-31.
  • 4Fadini GP, Boscaro E, Albiero M, et al. The oral dipeptidyl peptidase -4 inhibitor sitaglip- tin increases circulating endothelial progenitor cell in patients with type 2 diabetes [J]. Dia- betes Care, 2010, 33 (7) : 1607 -1609.
  • 5Jelsing J, Vrang N, van Witteloostuijn SB, et al. The DPP -4 inhibitor linagliptin delays the on- set of diabetes and preserves i3 - cell mass in non- obese diabetic mice [ J]. J Endocrinol, 2012, 214 (3): 381-387.
  • 6Kirino Y , Sato Y, Kamimoto T, et al. Inter- relationship of dipeptidyl peptldase IV (DPP4) with the development of diabetes, dyslipidaemia and nephropathy: a streptozoto- ein - induced model using wild - type and DPP4- deficient rats [ J ]. J Endocrinol, 2009, 200 (1): 53-61.
  • 7Garg R, Chen W, Pendergrass M. Acute pan- creatitis in type 2 diabetes treated with exenati- de or sitagliptin: a retrospective observational pharmacy claims analysis [ J ]. Diabetes Care, 2010, 33 (11): 2349-2354.
  • 8Derosa G, Ragonesi PD, Fogari E, et al. Sitagliptin added to previously taken antidia- betic agents on insulin resistance and lipid profile: a 2 - year study evaluation [ J ]. Fundam Clin Phannacol, 2012. doi : 10. llll/fcp. 12001. [ Epub ahead of print ].
  • 9赵文芬.二甲双胍治疗非酒精性脂肪肝的临床观察[J].山西医药杂志（下半月）,2007,36(7):499-500. 被引量：3
  • 10刘秀玲,项岫秀,李伟娟,俞芳,张慧芹,刘阁玲.二甲双胍治疗非酒精性脂肪肝临床疗效观察[J].中国综合临床,2009,25(5):478-479. 被引量：12

引证文献6

二级引证文献78

中国医院药学杂志
2013年 第13期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部